Lantheus/$LNTH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lantheus
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Ticker
$LNTH
Sector
Primary listing
Industry
Health Care Equipment and Supplies
Headquarters
Employees
808
ISIN
US5165441032
Website
Lantheus Metrics
BasicAdvanced
$5.1B
20.84
$3.53
0.12
-
Price and volume
Market cap
$5.1B
Beta
0.12
52-week high
$122.83
52-week low
$69.12
Average daily volume
1.1M
Financial strength
Current ratio
5.741
Quick ratio
5.191
Long term debt to equity
52.711
Total debt to equity
53.688
Interest coverage (TTM)
23.06%
Profitability
EBITDA (TTM)
515.083
Gross margin (TTM)
64.04%
Net profit margin (TTM)
16.55%
Operating margin (TTM)
29.43%
Effective tax rate (TTM)
28.61%
Revenue per employee (TTM)
$1,900,000
Management effectiveness
Return on assets (TTM)
14.55%
Return on equity (TTM)
24.11%
Valuation
Price to earnings (TTM)
20.844
Price to revenue (TTM)
3.313
Price to book
4.37
Price to tangible book (TTM)
5.36
Price to free cash flow (TTM)
12.986
Free cash flow yield (TTM)
7.70%
Free cash flow per share (TTM)
566.79%
Growth
Revenue change (TTM)
12.53%
Earnings per share change (TTM)
-45.68%
3-year revenue growth (CAGR)
41.57%
10-year revenue growth (CAGR)
17.63%
3-year earnings per share growth (CAGR)
85.26%
10-year earnings per share growth (CAGR)
42.11%
What the Analysts think about Lantheus
Analyst ratings (Buy, Hold, Sell) for Lantheus stock.
Bulls say / Bears say
Lantheus' Alzheimer's disease radiodiagnostic, MK-6240, met co-primary endpoints in two pivotal studies, demonstrating strong sensitivity and specificity in detecting tau pathology, with plans to submit a New Drug Application to the FDA in Q3 2025. (stocktitan.net)
The acquisition of Life Molecular Imaging Ltd. for up to $750 million, including $350 million upfront, expands Lantheus' presence in Alzheimer's disease diagnostics with Neuraceq, an F-18 PET imaging agent for β-amyloid plaque detection. (benzinga.com)
Lantheus' proprietary imaging agent, PYLARIFY, achieved over $1 billion in annual sales, indicating strong market demand and contributing to a 10.5% year-on-year sales increase in Q4 2024. (financialcontent.com)
The potential patent expiration of PYLARIFY in 2026 poses a risk to Lantheus' revenue stream, as the company seeks to extend protections and diversify its offerings. (wallstrank.com)
Insider selling activity, including Director Mary Anne Heino's sale of 53,107 shares on March 3, 2025, may raise concerns about internal confidence in the company's future performance. (etfdailynews.com)
The $350 million acquisition of Life Molecular Imaging led to a 4.4% drop in Lantheus' stock price, indicating investor apprehension about the financial impact of the deal. (benzinga.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
Lantheus Financial Performance
Revenues and expenses
Lantheus Earnings Performance
Company profitability
Lantheus News
AllArticlesVideos
Why Is Lantheus Stock Trading Lower On Wednesday?
Benzinga·2 days ago
Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
GlobeNewsWire·1 month ago
Lantheus to Present at the 2025 Truist Securities MedTech Conference
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lantheus stock?
Lantheus (LNTH) has a market cap of $5.1B as of July 18, 2025.
What is the P/E ratio for Lantheus stock?
The price to earnings (P/E) ratio for Lantheus (LNTH) stock is 20.84 as of July 18, 2025.
Does Lantheus stock pay dividends?
No, Lantheus (LNTH) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Lantheus dividend payment date?
Lantheus (LNTH) stock does not pay dividends to its shareholders.
What is the beta indicator for Lantheus?
Lantheus (LNTH) has a beta rating of 0.12. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.